Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to close in the second half of 2026, pending regulatory approvals. The divestiture […]
Astorg Makes Billion-Dollar Bet on Microbiology Testing
Sale of Thermo Fisher’s microbiology line reflects broader trend of prioritizing high-growth tests
- By Janette Wider
- > From the Volume XXXIII, No. 7 - May 26, 2026 Issue
- Tags: ADLM, AI, AMR, antimicrobial resistance, antimicrobial susceptibility testing, artificial intelligence, Association for Diagnostics and Laboratory Medicine, Astorg, bioMerieux, Blackstone, culture media, digital technology, Hologic, in vitro diagnostics, IVD, IVD Logix, ivd/lab informatics, Jennifer Zin, John Osiecky PhD, Journal of the American Medical Association, Larry Worden, Marc Casper, molecular testing, precision medicine, Private equity, Thermo Fisher Scientific, Today’s Clinical Lab, TPG
